三生制药
3SBIO INC.

2024 Interim Results Presentation

23 August, 2024

Disclaimer

This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only.

You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") before reading or making any other use of this document. In accepting the delivery of, reading or making any other use of this document, you acknowledge and agree to be bound by the Terms, and you agree to maintain absolute confidentiality regarding the information disclosed in this document in a manner consistent with the Terms. If you do not accept any of the Terms, in whole or in part, please immediately return this document to the Company.

These materials, and any further information made available to you, are highly confidential and are being given solely for your information. These materials, and any further information made available to you, form part of the proprietary information of the Company and may not be copied, reproduced, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization/firm) or published or otherwise disclosed, in whole or in part, in any manner and for any purpose without the prior written consent from the Company. Any forwarding, distribution or reproduction of this document, in whole or in part, is unauthorized.

The information used in preparing this document has not been independently verified and has not been reviewed by any regulatory authority in any jurisdiction. This document does not purport to provide a complete description of the matters to which it relates. No representation, warranty or undertaking, express or implied, is or will be made or given by, and no responsibility or liability is or will be accepted by, any person (for the avoidance of doubt, including but not limited to, the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing), with respect to the accuracy, reliability, correctness, fairness or completeness of this document or its contents or any oral or written communication in connection with this document. In addition, any analyses included herein are not and do not purport to be complete or comprehensive and are not and do not purport to be appraisals of the assets, stock or business of the Company or any of its holding companies, subsidiaries or other affiliates. Even when these materials contain a form of appraisal, it should be considered as preliminary, suitable only for the purpose described herein, subject to assumptions and not be disclosed or otherwise used without the prior written consent of the Company. The information in this document does not take into account the effects of a possible transaction or certain transactions which may have significant valuation and other effects. Nothing contained in this document is, or shall be, relied upon as a promise or representation as to the future or as a representation or warranty otherwise.

Nothing in this document constitutes or forms part of, or should be construed as constituting or forming part of, any regulatory, valuation, legal, tax, accounting, investment, or other advice. Nothing in this document constitutes or forms part of, or should be construed as constituting or forming part of, any recommendation, solicitation, offer or commitment to purchase, sell, subscribe for or underwrite any securities by any party, or to extend any credit or provide any insurance to you or to enter into any transaction, nor shall there be any sale of securities or other transaction in any jurisdiction in which such sale or transaction would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Unless otherwise agreed in writing, any third party from whom you receive this document is not acting as your financial adviser or fiduciary. Before you enter into any transaction, you should ensure that you fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisors and legal and/or tax experts. None of the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of, or reliance upon, the information contained herein by you or any person to whom the information herein is disclosed.

The contents of this document are subject to corrections or changes at any time without further notice. The information contained in these materials also contains certain forward-looking statements regarding the Company's intent, plans, beliefs, strategies, and growth prospects as well as the projected growth of China's economy and the pharmaceutical industry, which are based on various assumptions and subject to risks and uncertainties. In light of these assumptions, risks, and uncertainties, the future facts, events and circumstances described in these materials may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. The forward-looking statements are not guarantees of future performance. Each of the Company and its and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing assumes no obligation to (1) provide access to any additional information, (2) correct any mistakes or inaccuracies in this document, or (3) update or otherwise revise this document, for any reason whatsoever, including without limitation to reflect new information, events or circumstances that arise, occur or become known after the date of this document.

By receiving or reading this document, you acknowledge and represent to the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisors that (1) you are a "professional investor" as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and the rules made thereunder, have the knowledge and experience in financial and business matters, and are capable of evaluating the merits and risks of and conducting your own assessment of the Company and its shares, (2) you are a person into whose possession this document may lawfully be delivered in accordance with the laws of the jurisdiction in which you are located, and (3) you have conducted and will conduct your own investigation with respect to the Company and its shares and have obtained or will obtain your own independent advice relating to the investment in the shares of the Company, and, if located in the United States, are either a "qualified institutional buyer" or an institutional "accredited investor" as defined in the U.S. Securities Act of 1933, as amended, and the regulations enacted thereunder (the "U.S. Securities Act").

No information set out in this document will form the basis of or be relied upon in connection with any contract, commitment or investment decision. Any prospective investor will be required to acknowledge in any purchase contract that it has not relied on, or been induced to enter into such agreement by, any representation or warranty, save as expressly set out in such agreement. This document does not constitute, in whole or in part, an offer or invitation for the sale, purchase or subscription of any security. Any such offer or invitation will be made solely through a prospectus or offering circular in compliance with all applicable laws and any decision to purchase or subscribe for any security should be made solely on the basis of the information contained in such prospectus or offering circular issued in connection with such offer or invitation.

This document contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of the U.S. Securities Act; (2) to be a prospectus within the meaning of section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 38B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or (3) to have effected an offer to the public in the United States, Hong Kong or anywhere else without compliance with all applicable laws and regulations or being able to invoke any exemption available under all applicable laws and regulations and is subject to material change without notice. The distribution of this document may be restricted by law, and persons into whose possession this document comes should inform themselves of, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the applicable securities laws. The Company does not intend to conduct any public offering of securities in the United States, Hong Kong or anywhere else.

Agenda

1. Highlights
2. Business Overview
3. R&D
4. Financial Review
5. Q&A

01 Highlights

2024 Interim Results Abstract

Revenue

YOY **16.0%**



Net Profit Attributable to Owners of the Parent Adjusted for Non-Operating Items[1]

YOY **1.5%**



Gross profit

YOY **18.6%**

Gross profit ratio **86.5%**



EBITDA[2]

YOY **17.0%**



Net profit attributable to parent

YOY **11.1%**



Financial Resource

7.9 Bn

1. Adjusted items include: the interest expenses about CB redemption, the expenses associated with the share options and awarded shares, gain on redemption of 2025 Bonds, fair value gains or losses on financial assets, non-operating foreign exchange differences.
2. Adjusted EBITDA, period EBITDA excluding the above items

2024 Interim Highlights

R&D Progress

- SSS06: NDA accepted for review in CKD anemia
- TPIAO：Ph III study in CLDT met endpoints
- Winlevi®：Ph III bridging trial in 12 years old+ the acne vulgaris is enrolling patients
- 608 (IL-17A Ab): Ph III study in adult moderate-to-severe PsO completed W52 work and met all primary endpoints
- 611 (IL-4R Ab): Ph II study in CRSwNP has met endpoints
- 613 (IL-1β Ab) : Ph II study in the intermittent phase of gouty arthritis completed enrollment
- 707 (VEFG/PD-1 BsAb): Ph II in NSCLC start enrollment; IND of Ph II studies in CRC etc. got approved
- 626 (BDCA2 Ab): Submitted China& U.S. IND application, China IND application was accepted by NMPA

Shareholder Returns

- Dividends and repurchase amount totaled 860mn HKD, accounting for over 40% of net profit of 2023
- Dividends distributed 600mn HKD, dividend ratio 4.1%[1]
- Repurchased 270mn HKD, rank ahead among healthcare companies in HK stock market[2]

BD

- **Semaglutide:** gained the R&D and commercialization rights of the product for weight management in China, Mexico and the gulf countries.

Financial Management

- Obtained the IFC long-term low-interest loan credit of US $200 million equivalent
- The debt ratio was reduced to 29.5%, and the half-year comprehensive financial cost was 23 million yuan

Sales Growth

TPIAO	EPO	Yisaipu	Cipterbin	Mandi
Revenue **2.5** bn	Revenue **516** mn	Revenue **329** mn	Revenue **162** mn	Revenue **550** mn
YOY **22.6**%	YOY **11.3**%	YOY **9.5**%	YOY **48.9**%	YOY **10.0**%

1. Dividend ratio: Based on the closing price on the dividend date
2. Data source: Wind

02 Business Overview

Biopharmaceuticals

TPIAO- Global Exclusive Commercialized rhTPO

Revenue of TPIAO, 2024H1

RMB Mn

1

Top 1 market share

66% [1] market share in terms of sales, still tops the first position in rhTPO products



TPIAO　Class A（Interleukin-11）　Class B（Oral TPO-RA）

1.Data source： IQVIA , Total market volume includes TPO, interleukin-11,-bopag and Romiplostim

TPIAO- Improving Patients Coverage



1Mn | **Chemotherapy TCP**
Persistent foundation work in the CTIT treatment

300k | **Radiotherapy TCP**
If PLT<75*10^9, treatment interruption rate is close to 50%

200k | **Surgery TCP**
If the surgical incision is larger, PLT should be higher than 100*10^9

TPIAO- Improving Clinical Recognition

Liver Diseases

APASL

The Annual Meeting of the Asian Pacific Association for the Study of the Liver

“Standard for diagnosis and treatment of primary liver cancer (2024 edition)”

CLDT

CLDT patients who are candidates for invasive surgery

March, 2024

- Several studies of rhTPO showed in APASL, shared academic achievements in acute liver failure, acute-on-chronicliver failure (ACLF), liver cancer ablation severe thrombocytopenia (sTCP) etc.



May, 2024

- “Standard for diagnosis and treatment of primary liver cancer (2024 edition)”released, Recommend rhTPO to treat Chronic liver disease related thrombocytopenia（CLDT）

July, 2024

- Phase III study of TPIAO treating CLDT patients who are candidates for invasive surgery has met primary endpoints

Nephrology

Kidney Transplant Recipients TCP

June, 2024

- “Clinical diagnosis and treatment guidelines for long-term systemic complications in kidney transplant recipients in China” released, Recommend rhTPO to treat kidney transplant recipients TCP


中国肾脏移植受者远期系统并发症临床诊疗指南

Sepsis

Lower the sepsis mortality rate

July, 2024

- The study results of rhTPO for sepsis released that rhTPO could through Mpl combination stimulate the PI3K/Akt channel, reduce levels of IL-6 and TNF-α inflammatory factors, ameliorated endothelial injury, and lower sepsis mortality rate

rhEPO- EPIAO & SEPO

Revenue of rhEPO, 2024H1

RMB Mn

1

TOP 1 Market share

Two brands dominate **43%**[1] market share, preside Top 1 position in terms of EPO market share

- EPIAO® quality standard is consistent with **EU Pharmacopeia**
- Treatment guidelines[2] promoted standardized treatment, penetration rate in CIA continues to enhance
- Perioperative anemia included in 2023 NRDL payment, open the potential market with **millions of patients**



1. Data source of market share: IQVIA
2. “Practice Guidelines for Cancer Induced Anemia 2022” added 36000IU for primary recommendations for MDS; .NHC “ 2021 Document for Improvement of Quality Control ([2021] no.51) ”

Yisaipu- Explore to Reform

Revenue of Yisaipu, 2024H1

RMB Mn

Market penetration rate improved

- Enhance hospitals coverage and related department coverage, prompt market penetration

Expand new formulation

- Pre-filled injection got approval and marketed in May 2023

Persistent foundation work

- Promote NEDL entry and rural revitalization projects, improve treatment level of foundation institutions

Cipterbin- Provide More Choice for Patients

Revenue of Cipterbin, 2024H1

RMB Mn

HER2-positive advanced breast cancer H treatment Grade I recommendations

Grade I recommendations: (1) THP[1] (IA); (2) TXH[2] (2A)

--Anti-HER2 mAb (H), including commercialized Trastuzumab, biosimilars, **Inetetamab**



- Covered hospitals continue to increase
- Accumulation of evidence for EBM, recognition from doctors and patients improved
- Advanced accessibility of the drug

1. Combined Taxotere, anti-HER2 mAb and Pertuzumab together therapeutic schedule
2. Combined Taxotere, Xeloda and anti-HER2 mAb together therapeutic schedule

Dermatology

Mandi – Effective & Reliable Hair Growth Drug

Revenue of Mandi, 2024H1

RMB Mn

YOY：10.0%

- Mandi (5% minoxidil) got the highest endorsement level of recommendation in female androgenetic alopecia (FAGA)
- Mandi ranked No.1 among “Dermatology chemical drugs” in 2023 Chinese OTC list

- Upgrade **digital operation** system, improve conversion efficiency
- Create **diversified product portfolio** depending on technical advantages, cover more needs about hair growth
- 618 GMV won **No.1** among Tmall health OTC drugs**, market share improved**

1. Market share data source: CPA

Mandi- Build Product Matrix, Expand Brand Value

1st Generation

Mandi Tincture

- Mandi (60mL, 90mL)
- Mandi Pro (10mL)
- Mandi for Female (30mL)
- Mandi Mini bottle (10mL)

2nd Generation

Mandi Foam

Approved with OTC in Jan 2024;
Innovative technology, fill the gap for skin sensitive population

Daily Chemical products

- Mandi “Stand on” Shampoo, conditioner
- Selenium disulfide anti-dandruff shampoo
- Mandi Comb

New Choice for Teenagers in Acne- Winlevi®

Winlevi® (clascoterone) cream 1%

WS204 Clascoterone cream

Acne vulgaris in 12 years and older

Bridging Trial | **Phase III**

Face domestic millions of adolescent patients

Safe, Effective, Convenient drug

Clinical trial shows:

Winlevi® could reduce the emergence of acne, blackheads, whiteheads

W4 treatment observes acne reduced;

W12 treatment shows obvious improvement

WINLEVI® is the only cream for acne treatment targeting sebum production

--By inhibiting the activity of sebaceous androgens and reducing sebum production to reduce inflammation[1]

1st new mechanism of action in acne approved by the FDA in 40 years

- Approved by FDA in November 2021[1]

12 years older

- Global 1st external topical androgen receptor inhibitor for the acne vulgaris in patients aged 12 years or older

1.09 mn

- Winlevi® is already the most prescribed branded topical acne drug in the US . By June 2024, it generated over 1.09 mn prescriptions[2]

1：www.winlevi.com

2：Cosmopharma 2024 Interim Report

Face Weight Management Broad Market- Semaglutide

Chinese number of obese people (Est. 2030):

329 mn[1]



Forecast of Chinese weight loss drug market size[1]



Semaglutide: Globally recognized safe and effective weight management products

- Dec. 2017
  FDA approved **diabetes mellitus type 2**
- Jun. 2021
  FDA approved **weight management**
- Mar. 2024
  FDA approved **heart disease protection in obese patients**
- Jun. 2024
  NMPA approved **weight management** i

Mean weight loss occurred within 68 weeks

The risk of cardiovascular events was reduced

- In May 2024

Achieve cooperation on Semaglutide injection weight management indication

The first batch of IND approval in China	Reach a wide range of people online	Sectors echelon layout

1. Data source: Frost Sullivan, http://m.cnpharm.com/c/2021-09-22/803749.shtml

03 R&D

R&D Pipeline

Therapeutic Area	Candidates	Pre-clinical	IND	Ph I	Ph II	Ph III	NDA
Nephrology	SSS06 Long-acting rhEPO						NDA
	RD01 Long-acting rhEPO						
	TRK-820 Remitch CLD pruritus						
	SSS17 HIF inhibitor						
Hematology and Oncology	TPO-106 CLDT						
	304R anti-CD20 Ab						
	CS1003 anti-PD1 Ab						Licensed product in Mainland China
	602 anti-EGFR Ab						
	302H anti-HER2 Ab						
	609A anti-PD1 Ab				U.S. Ph I		
	707 anti-PD1/VEGF BsAb				U.S. IND		
	705 anti-PD1/HER2 BsAb			U.S. IND			
	SA102 CS1/BCMA CAR-T						
	SSS41 CAR-T						
	SSS20 Eltrombopag						ANDA
	Eltrombopag suspension						ANDA
Auto-immune, Ophthalmology and others	608 anti-IL17A Ab						
	601A anti-VEGF Ab						
	613 anti-IL1β Ab						
	611 anti-IL4Rα Ab					U.S. Ph Ia	
	610 anti-IL5 Ab						
	SSS07 anti-TNFα Ab						
	SSS11 Pegsitocase						
	SSS40 anti-NGF Ab						
	621 anti-IL33 Ab			U.S. IND			
	SSS39 Rapamycin Nanoparticle						
Dermatology	WS204 Clascoterone						
	Semaglutide						

Small Molecule Antibody Others

- 2 Pre-clinical
- 6 IND& Phase I
- 6 Phase II
- 12 Phase III &NDA
- 2 BE/ANDA
- 2 Approved NDA or ANDA in 2024H1

Key Candidates — Nephrology

SSS06 NuPIAO（rESA）

CKD anemia

NDA accepted for review

Cancer related anemia (CRA)

Phase II

Remitch (Narfuraphine hydrochloride orally disintegrating tablets)

CLD induced pruritus

Phase III

SSS17 HIF inhibitor

CKD anemia, postoperative anemia (Exp. develop)

Phase II

SSS06

Glycosylation sites modified EPO

- Extend half-life, dosing at longer intervals, match treatment cycles of chemotherapy patents
- NDA accepted for review
- Rank No.2 among domestic peers

10% CIA Penetration rate

2024 NDA

Remitch

Narfuraphine hydrochloride orally disintegrating tablets

Dialysis pruritus targeted patients

>300k

CLD pruritus targeted patients

>1 Mn

- The incidence of pruritus ranges from 5% to 70% in different types of liver diseases
- Current treatment are not effective to over **57%** liver disease pruritus

Alcoholic fatty liver disease, 62 mn

Liver cirrhosis | Hepatitis C

chronic hepatitis B 90 mn

Non-alcoholic fatty liver disease (NAFLD) 170-310 Mn

2024 Est. NDA

Key Candidates — Hematology / Oncology

TPO-106

CLDT (Phase III study met endpoints)

NDA preparing

Cipterbin

Her2- positive breast cancer neoadjuvant

Phase II

707 (VEGF/PD-1 BsAb）

NSCLC, mCRC, Advanced gynecologic tumors

Phase II

Explore New Indication

TPIAO： Recommended in the treatment of **HRT** in the “Chinese expert consensus on the clinical management of hepatopathy-related thrombocytopenia”

Cipterbin: explore applications in Her2- positive breast cancer **neoadjuvant,** cover more breast cancer patients

2024 ASCO conference published few reports that Inetetamab

1) Combined with Pyrotinib and nab-paclitaxel for early-stage and locally advanced HER2-positive breast cancer neoadjuvant
2) Combined with Pyrotinib and chemotherapy for early-stage and locally advanced HER2-positive breast cancer neoadjuvant released significant data
3) Various combinations for metastatic/ advanced HER2-positive breast cancer 1L/ 2L treatment and neoadjuvant study results updated



Develop New Molecule



CLF²（common light chain Linear-Fabs-IgG）BsAb platform

707 (VEGF/PD-1 BsAb):

- Depend CLF² patent platform and developed anti-VEGF/PD-1 BsAb
- Conducted phase II studies in 1L & combined with chemotherapy 1L advanced NSCLC, mCRC indications etc., U.S. IND approved

Key Candidates — Autoimmune

Focus on broad Chinese autoimmune market



LN: lupus nephritis
IBD: inflammatory bowel disease
SLE: systemic lupus erythematosus
PN: prurigo nodularis
AS: ankylosing spondylitis
PsO：psoriasis
CRSwNP: chronic rhinosinusitis with nasal polyps
CSU：chronic spontaneous urticaria
BA: asthma
AD: atopic dermatitis
COPD: chronic obstructive pulmonary disease



The patient population in autoimmune diseases is huge

Key Candidates — Autoimmune

Build the most competitive autoimmune pipeline in China

	Indication	IND	Ph I	Ph II	Ph III	NDA
608 anti-IL-17A Ab	Moderate-to-severe PsO					2024E
	AS					
	Nr-axSPA					
613 anti-IL-1β Ab	Acute Gout Arthritis					2025E
	Intermittent phase of gout arthritis					
611 anti-IL-4R Ab	Adult AD					2026E
	CRSwNP					
	Adolescent AD					
	COPD					
	AD (U.S.)					
610 anti-IL-5 Ab	Eosinophilic asthma					2027E
621 anti-IL-33 Ab	COPD					

Autoimmune pipeline strategy

Indications coverage of marketed products	Product pipeline development, effort to build FIC/BIC products	The new indications include AD, CRSwNP, COPD, moderate to severe asthma, acute gouty arthritis, etc
RA、AS、PsO		



608 (anti-IL-17A mAb): Phase III in PsO Completed

Phase III study data in PsO unblinds: met primary endpoints and all secondary endpoints

	Primary endpoints		Key secondary endpoints			Secondary endpoints		
	PASI 75 (W12)	sPGA 0/1 (W12)	PASI 90 （W12）	PASI 100 （W12）	PGA 0 （W12）	maintenance -PASI100 （W52）	DLQI[1]	Pruritus NRS[2]
608 160+80 mg Q2W	95.1%	76.1%	√	√	√	63.6%	√	√
608 160mg Q4W	93.4%	67.2%	√	√	√	56.8%	√	√

- The primary efficacy data at 12 weeks were excellent, with rapid response rate and obvious efficacy advantages
- In the maintenance treatment period, the 608 dosing interval was extended to Q4W or Q8W, and the efficacy remained high, which was expected to achieve a longer dosing interval in PsO

2024
Est. NDA

The efficacy of 608 compared with its peers (W12 response rate)



Note: SEC- Secukinumab, IXE- Ixekizumab

1. DLQI: Dermatology Life Quality Index, 2. Pruritus NRS: Pruritus Numerical Rating Scale

611 (anti-IL-4R mAb): Phase II in CRSwNP Completed

Phase II study in CRSwNP shows significant efficacy

- **The W16 data showed that the efficacy of all 611 doses (Q2W and Q4W) was clear and significantly better than that of placebo**
- **At the same dose, the response of 611 NPS tended to be higher than that of marketed drugs with the same target**

Dosage group	NPS[2]	NCS[2]
W16 changes from baseline		
611 GroupA[1] N=33	**-2.11**	**-1.11**
611 GroupB[1] N=34	**-1.61**	**-1.16**
W24 changes from baseline		
Dupilumab (Q2W)	-1.71~-1.89	-1.25~-1.34



- The safety data of 176 cases showed that the incidence of TEAE in 611 studies was lower than that of similar products at the same dose
- The incidence of common adverse events was lower than that of similar products



1. 611 Group A representative: 300mg Q2W, Group B representative: 450mg Q4W;
2. NPS: Nasal polyps score under bilateral nasal endoscopy; NCS: Mean weekly nasal congestion score

Early R&D Layout - Multiple Mature New Drug Development Platforms, Multi-dimensional Screening and Evaluation of Druggability

A comprehensive research, production and marketing mature system, covering the whole process of antibody discovery, development, registration, clinical study, production and commercialization, multiple mature drug R&D platforms, multi-dimensional screening and evaluation of druggability

BsAb & Multispecific Ab Platform

1

- Multifunctional, new mechanism, distinct druggability, helpful to product

Multifunctional Fc Protein Platform

2

- Discover new function based on new mechanism, diversified forms

Ab Maturity and Optimization Platform

3

- Humanized, improve physicochemical properties, mature affinity, function expansion and optimization

Ab Selection Platform

4

- Facilitate new targets R&D, Convenient, fast, costs-controllable R&D

Pre-clinical Animal Drug Effect Platform

5

- Convenient, fast, costs-controllable, on-demand design for explore new mechanism, mouse, rat, rabbit etc. multi-species project design

1 Expression

Macromolecular protein expression is closely related to its structural stability and is also an important factor for subsequent commercialization cost

2 PD (In vitro)

Molecular level of affinity, activation or blockade of cell signaling pathways consistent with MOA, endocytosis efficiency, cell killing activity (ADCC, ADCP, CDC), etc.

3 PD (In vivo)

The pharmacodynamic activity of different animal models, in vivo pharmacodynamic activity of different models of the same species, ways of administration, dosage, dosage form, etc

4 Physicochemical Property

Aggregation propensity, fragmentation, charge heterogeneity, oxidation, isomerization, and deamidation

5 PK (In vivo)

Mouse/monkey in vivo PK data (AUC, Cmax, Tmax, VD, CL, T1/2), immunogenicity, neutralizing ADA

6 Toxicity (In vivo)

General toxicology, acute toxicity, prolonged toxicity and reproductive toxicity, off-target effects, tissue cross-reactivity

7 CMC

The expression level and passage stability of cell lines, antibody homogeneity (antibody chain mismatch, loss or mismatch, molecular breakage during production or purification, a variety of modifications), antibody aggregation, thermal stability, light sensitive stability, pH sensitive stability, freeze-thaw stability, etc

8 IP

Patent space, patent novelty, patent stability, etc

SSGJ-626: 2nd Generation BDCA2 mAb with BIC Potential

	SSGJ-626
Mechanism	Through inhibiting plasmacytoid dendritic cell (pDC), the secretion of IFNα was inhibited. Thus regulating the activity of a range of immune cells
BDCA2 affinity	**Strong** (KD: 2.48E-11)
Degree of humanization	**Very high** (There were no revertant mutations in either light or heavy chain)
Inhibit the secretion of IFNa and IgM	**Very strong** (IC_{50} 20 folds+ stronger thanLitifilimab)
In vivo efficacy in animals	**Strong**
Fc function optimize	Extend PK, strengthen Fc effect
R&D Situation	Submitted IND application in China and U.S. in July China IND application got approved

Anti-BDCA2 Ab: SLE Ph II shows significant efficacy

- Two hallmarks of SLE are IFNa and anti-nucleic acid autoantibody, so it has been proved that targeting IFNa and B cells (producing antibodies) can effectively control the disease
- Disclosed clinical data show that Litifilimab has shown promising efficacy in clinical phase II trials in SLE

Huge Marketing Potential

- The global market for SLE drugs is expected to reach **US $16.9 billion in 2030**, of which biologics will reach **US $14.2 billi**on, while the Chinese market is expected to reach **US $4.3 billion**, of which biologics will reach **US $3.2 billion**
- **Benlysta**, anti-B Lymphocyte stimulator (BLyS) mAb, its annual global sales in 2023 reached **$1.63 billion**, with a growth rate of **18%** compared to 2022
- **Anifrolumab**, the anti-IFNaR mAb developed by AZ, which will be launched in July 2021, will achieve annual sales of **$280 million** in 2023 and is expected to become a blockbuster drug with annual sales of **more than $1 billion** in 2029
- **Litifilimab**, Biogen's anti-BDCA2 mAb met all primary and secondary endpoints in two CLE and SLE Phase II trials, and multiple Phase III trials are currently underway

Key Candidates Outlook

Est. NDA Time:	2024E	2025E	2026E	2027E~
Hematology/ Oncology	TPIAO CLDT	CS1003 (PD-1 Ab) Advanced HCC		
Dermatology		Winlevi ® 12 years+ acne vulgaris	Semaglutide injection Weight management	
Autoimmnue	608 (IL-17 Ab) Moderate-to-severe PsO	613 (IL-1β Ab) Acute gout arthritis	611 (IL-4R Ab） Adult AD	610 (IL-5 Ab） Eosinophilic asthma
Nephrology	SSS06 (long-acting EPO) CKD anemia		SSS17 (HIF inhibitor) Postoperative anemia	

04 Financial Review

Financial Analysis

Revenue

16.0% YOY



Gross Profit

18.6% YOY

Gross profit ratio: **86.5%**



Net Profit Attributable to Parent

11.1% YOY

Net Profit Attributable to Owners of the Parent Adjusted for Non-Operating Items

1.5% YOY

R&D Costs Ratio Improved



R&D Costs Ratio		Selling and Distribution Expenses Ratio		Administrative Expenses Ratio		Comprehensive Finance Costs Ratio	
2023H1	2024H1	2023H1	2024H1	2023H1	2024H1	2023	2024H1
8.1%	10.8%	36.3%	36.3%	5.7%	4.6%	0.8%	0.5%

R&D Costs

- Semaglutide BD deal
- BsAb etc. R&D promotion
- Early-stage target develop

Comprehensive Finance Costs Ratio decreased

- Interest revenue and Financing costs totaled 23 mn
- Comprehensive Finance Costs ratio 0.5%, decreased with comparison with 0.8% of 2023

Obtained IFC Long-tern Loan Credit

三生制药 3SBIO INC.

IFC International Finance Corporation WORLD BANK GROUP

中华人民共和国财政部
Ministry of Finance of the People's Republic of China

国际财金合作司

国际金融公司执董会批准三生制药贷款项目

2024年3月18日，国际金融公司（IFC）执董会按简化程序批准了三生制药贷款项目。三生制药集团总部位于辽宁沈阳，主要从事开发生物制药产品，以解决在癌症及护理、肾脏病学以及其他领域的重大医疗需求。

IFC 拟向三生制药集团提供两笔总额最高为2亿美元等值的7 年期人民币贷款，以支持和改善创新药在中国以及其他发展中国家的供应和可负担性。

发布日期：2024年03月28日

Obtained International Finance Corporation (IFC) granting

$ 200 mn

equivalents long-term low-interest loan credit

The first partner of IFC in the biopharmaceutical industry in China

This year's largest funding project in the biopharmaceutical industry

Further optimized the company's cash flow and financing structure

Supported by IFC's international resources to help the company explore overseas emerging markets

It is also an excellent practice for Chinese biopharmaceutical enterprises in the ESG field

Asset Structure Optimized

	2024H1	2023
Total Assets	23.6 Bn	23.6 Bn
Net Assets	16.5 Bn	16.5 Bn
Debt Asset Ratio	30%	30%

ROE[2]

Improved to **13.1%**



Net Assets

Gearing Ratio[1]



1. Gearing ratio = (Long-term& short term liabilities+ bonds payable + lease liabilities) / net assets
2. Annual ROE

Abundant Cash Asset Reserves

Operating Net Inflow

1.1 Bn

Financial Resource

7.9 Bn



Our Future BD Strategy

Sufficient Financial Resource

Nearly **RMB 8 bn** available
Over **RMB 2 bn** operating cash net inflow annually

Flexible Cooperation Model

Support diverse cooperation model such as **license-in, CSO, CDMO, lisence-out etc. ,** exploring more opportunities with our partners

Professional R&D Support

Near 700 scientists, accounting for **over 10%** of total staff, R&D expense of **over 10% of revenue**

License-Out

- Promote the innovative products independently developed by the Group's technology platform to go to **the global market**
- Complementary advantages, actively cooperate with external partners to maximize **the commercial value** of innovative products

License-In

- Combined with marketing resources, allocated of high-value blockbuster products in advantageous field to achieve continuous expansion of **commercial scale**
- Strategic layout medium and long-term echelon construction of pipelines, seek **new targets, new technologies,** committed to meet clinical unmet needs

Comprehensive Facilities

6 manufacturing plants with **100KL+** cost-effective manufacturing capabilities, covering **small molecule, large molecule, CGT, mRNA** etc.

Strong Commercialization Platform

Near 3,000 sales and marketing employees
Experienced digital marketing team
Covers **over 2,900** Grade III hospitals and altogether around **10,000** hospitals

Focused Therapeutic Area

Focus on advantageous therapeutic area, including **hematology, oncology, nephrology, autoimmune, dermatology etc.**

Advancing ESG Governance

北京仁泽公益基金会
BeiJing RenZe Foundation

红遍中国

益肾论道 - 基石引领经典 -

- Take social responsibilities , devote to public welfare actively
- Support “Ankylosing Spondylitis Healthy Village Program”, Aided and treated cumulative thousands of patients in AS, cancer, dialysis etc.
- ESG governance retained the **AA** rating by MSCI, exceeding **84**% biotech companies worldwide
- Rated Wind ESG A rating
- Won the 2024 Yinghua Award of Hong Kong Stock ESG Value Award of China Listed Companies



05 Q&A

THANKS

3SBio Inc. (1530.HK)
Investor Relations
ir@3sbio.com

珍 爱 生 命 · 关 注 生 存 · 创 造 生 活

CHERISH LIFE CARE FOR LIFE CREATE LIFE